Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43722   clinical trials with a EudraCT protocol, of which   7255   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2018-002263-26
    Sponsor's Protocol Code Number:P180101
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2019-01-30
    Trial results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2018-002263-26
    A.3Full title of the trial
    Optimizing response to Li treatment through personalized evaluation of
    individuals with bipolar I disorder
    Optimierung des Ansprechens auf eine Lithium-Behandlung durch eine personalisierte Evaluation bei Patienten mit einer Bipolar-I-Störung
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Optimizing response to Li treatment through personalized evaluation of
    individuals with bipolar I disorder
    Optimierung des Ansprechens auf eine Lithium-Behandlung durch eine personalisierte Evaluation bei Patienten mit einer Bipolar-I-Störung
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code numberP180101
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAssistance Publique - Hopitaux de Paris
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportDRCI APHP
    B.4.1Name of organisation providing supportEuropean Commission
    B.4.2CountryEuropean Union
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAssistance Publique - Hopitaux de Paris
    B.5.2Functional name of contact pointProject Manager
    B.5.3 Address:
    B.5.3.1Street Address1, avenue Claude Vellefaux
    B.5.3.2Town/ cityParis
    B.5.3.3Post code75010
    B.5.4Telephone number+33144841793
    B.5.5Fax number+33144841701
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 554-13-2
    D.3.9.3Other descriptive nameLITHIUM CARBONATE
    D.3.9.4EV Substance CodeSUB14375MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number to 450
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Adult individuals with bipolar I disorders who initiate lithium treatment
    based on the decision of themselves and their clinician
    Patienten mit einer Bipolar-I-Störung bei denen Arzt und Patient die Entscheidung zum Beginn einer Lithium-Therapie getroffen haben
    E.1.1.1Medical condition in easily understood language
    Adult individuals with bipolar I disorders who initiate lithium treatment
    based on the decision of themselves and their clinician
    Patienten mit einer Bipolar-I-Störung bei denen Arzt und Patient die Entscheidung zum Beginn einer Lithium-Therapie getroffen haben
    E.1.1.2Therapeutic area Psychiatry and Psychology [F] - Mental Disorders [F03]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10057667
    E.1.2Term Bipolar disorder
    E.1.2System Organ Class 10037175 - Psychiatric disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The objective of this study is to identify the eligibility criteria for
    treatment with Li in BDI in terms of response, safety and tolerability

    Primary Objective: To classify the participants according to different definitions of Lithium response
    Ziel der Studie ist es, prädiktive Faktoren für eine Lithiumtherapie von BDI-Patienten im Hinblick auf Ansprechen, Sicherheit und Verträglichkeit zu identifizieren
    Primäres Ziel der Prüfung: Klassifizierung der Patienten nach Ansprechen auf Lithium
    E.2.2Secondary objectives of the trial
    To evaluate the prognostic values of the biomarkers collected during the
    first three months of Lithium treatment on long term Lithium response
    (2 years)
    Evaluation des prädiktiven Wertes von während der ersten drei Monate einer Lithiumbehandlung gesammelten Biomarkern im Hinblick auf das Langzeitansprechen (2 Jahre)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Decision to prescribe Li as a prophylactic treatment based on
    clinicians' assessment
    2. Confirmed diagnosis of BD1 according to DSM-5 criteria [based on
    the Mood section of the SCID]
    3. Aged 18-70 years.
    4. Able and willing to give written informed consent
    Entscheidung, eine Lithiumbehandlung zu beginnen vor Einschluss in die klinische Studie
    Diagnose einer bipolaren Störung BD1 gemäß DSM-5 Kriterien
    Teilnehmer/innen zwischen 18 und 70 Jahren
    schriftliche Einwilligung nach erfolgter Aufklärung
    E.4Principal exclusion criteria
    1 Trial of Lithium undertaken within the last 6 months
    2 Lifetime history of mood disorder better explained by a DSM-5
    definition for schizoaffective disorder [based on the relevant section of
    the SCID]
    3 Pre-lithium screening suggest that Lithium initiation is
    4 Participation in another research protocol that interferes with the
    evaluation of Lithium response (efficacy or tolerance)
    5 Severe risk of self-harm at present, based on clinician's evaluation
    6 Protected adult
    Teilnahme an einer Studie mit Lithiumbehandlung innerhalb der letzten sechs Monate vor Beginn der Studie
    Schizoaffektive Störung gemäß DSM-5 Kriterien in der Vorgeschichte
    Anzeichen für eine Lithium-Kontraindikation im entsprechenden Screening:
    Teilnahme an einer anderen interventionellen klinischen Prüfung innerhalb der letzten vier Wochen
    Hohes Risiko der Selbstgefährdung nach Einschätzung des behandelnden Arztes
    Personen mit bestehender oder vorgesehener gesetzlicher Betreuung
    E.5 End points
    E.5.1Primary end point(s)
    After all study participants have completed the follow-up period, the
    expert panel will reach a consensus on the classification of each
    participant into one of three categories: (i) good responders (GR), (ii)
    partial responders (PR), (iii) non-responders (NR). If no clinical followup
    data are available, the participant will be categorized as
    unclassifiable (UC).
    Klassifizierung der Lithiumresponse aller Studienteilnehmer/innen nach Beendigung der Follow-up-Periode durch ein Expertengremium in eine der drei Kategorien (i) „good responders“ (GR), (ii) „partial responders“ (PR) oder (iii) „non-responders“ (NR) zuordnen. Wenn keine Followup-Daten vorliegen, wird der/die entsprechende Studienteilnehmer/in als „unclassifiable“ (UC) kategorisiert.
    E.5.1.1Timepoint(s) of evaluation of this end point
    After all study participants have completed the follow-up period
    wenn alle Studienteilnehmer die Followup-Periode beendet haben
    E.5.2Secondary end point(s)
    There are several possible definitions of treatment response that employ
    different levels of precision.
    a) - Response assessed retrospectively by estimating the total score on the Retrospective Longitudinal Evaluation of Lithium Response, also known as the "Alda" Scale
    - Comparison of the BDI illnesss activity for the two years pre-/post-Li Initiation ("mirror Image" design)
    b) Time dependent measures of Outcome
    - time to a new BD Episode (defined as Meeting DSM-5 diagnostic criteria after a period of euthymia (for a Minimum of 8 weeks)
    - time to a new hospitalisation for BD
    - time to prescription of a new mood stabilizer (either an adjunct or alternative to Lithium)
    c) Continuous ratings of BD symptoms
    a) Alda Scale
    Vergleich des BD I vor und nach 2 Jahren Lithiumeinnahme
    b) zeitabhänige Messungen des Ergebnisses
    - Zeitspanne bis zu einer neuen affektiven Episode(nach mind. 8 Wochen Euthymie)
    - Zeitspanne bis zu einer Hospitalisierung aufgrund einer neuen affektiven Episode
    - Zeitspanne bis zur Verordnung eines neuen Medikamentes zur Stimmungsstabilisierung
    c)Kontinuierliches Rating von BD-Symptomen
    E.5.2.1Timepoint(s) of evaluation of this end point
    monthly visits (face to face or telephone) for 24 months
    monatliche Visiten (Vor Ort oder telefonisch) für 24 Monate
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA16
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Letzte Visite des letzten Patienten
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months48
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months48
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 290
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 30
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state60
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 320
    F.4.2.2In the whole clinical trial 320
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-06-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-08-13
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands